With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.578743-87-0,[1,3-Bis(2,6-diisopropylphenyl)imidazol-2-ylidene]copper chloride,as a common compound, the synthetic route is as follows.
l-(lH-benzimidazol-2-yl)-isoquinoline (46 mg, 0.19 mmol) was dissolved in 10 mL of dry THF under N2 and this solution was transferred via cannula to suspension of sodium hydride (8.36 mg, 0.209 mmol, 60% in mineral oil) in dry THF. The reaction mixture was stirred at RT for 1 h and then chloro[l,3-bis(2,6-di-i-propylphenyl)imidazol-2- ylidene]copper(I) (92.6 mg, 0.19 mmol) was added. The reaction mixture was stirred at RT for 3 h. The resulting mixture was filtered through Celite and solvent was removed by rotary evaporation. Recrystallization by vapor diffusion of Et20 into a CH2C12 solution of product gave 50 mg (38%) of orange crystals.
578743-87-0 [1,3-Bis(2,6-diisopropylphenyl)imidazol-2-ylidene]copper chloride 0, acopper-catalyst compound, is more and more widely used in various.
Reference£º
Patent; THE UNIVERSITY OF SOUTHERN CALIFORNIA; THOMPSON, Mark; DJUROVICH, Peter; KRYLOVA, Valentina; WO2011/63083; (2011); A1;,
Copper catalysis in organic synthesis – NCBI
Special Issue “Fundamentals and Applications of Copper-Based Catalysts”